Medical professionals discuss strategies and best practices for recognizing and mitigating immunotherapy toxicities through multidisciplinary collaboration and use of monitoring technology.
This is a video synopsis/summary of a Peer Exchange involving Jason Luke, MD, FACP; Christopher Barker, MD; Omid Hamid, MD; Vishal Patel, MD; and Catherine Pisano, MD.
Pisano outlined the coordinated intake process at her center, including a dedicated nonmelanoma tumor board with dermatology, medical and radiation oncology, head and neck surgery, and surgical oncology. This enables rapid pathology review, imaging access, and subspecialty evaluations so patients start optimized treatment quickly. Luke noted the importance as a medical oncologist of seeing geographically distant patient referrals, as the clinical scenario may differ from the referral details. He suggested medical oncologists should view themselves as quarterbacks to appropriately triage and coordinate care. Patel agreed playing this role and having at least an initial discussion enables complex patients to get connected to local treatment. Hamid stated current technologies facilitate coordination, including virtual video visits with patients to obviate travel and easily convening joint tumor boards. While subspecialists need not attend weekly meetings, periodic participation allows for information dissemination and ensures evidence-based care. The discussants concluded leveraging technology solutions can enhance collaboration to raise the standard of care for patients regionally and nationally.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More